Merck

Healthcare

Founded in 1891 by George Merck, Merck & Co. (MSD outside the US and Canada) is a global biopharmaceutical leader developing life-saving medicines, oncology therapies, and vaccines.

View Official Merck Careers

Official Merck Careers Website

Quick Facts

Founded: 1891
Founder: George Merck
Headquarters: Rahway, New Jersey
Public Ticker: NYSE: MRK

About Merck

Merck & Co., Inc. was established in New York in 1891 by George Merck as the U.S. subsidiary of German chemical company E. Merck (Darmstadt). Following WWI, it became an independent American biopharmaceutical corporation headquartered in Rahway, New Jersey.

Merck generates over $60 billion annually as one of the world's largest pharmaceutical companies. Famous for its anti-PD-1 cancer immunotherapy Keytruda, HPV vaccine Gardasil, diabetes treatments, and infectious disease therapies, Merck operates across human health and animal health divisions worldwide.

What Merck Does

Oncology (Keytruda)

World-leading cancer immunotherapy Keytruda targeting lung, melanoma, renal, and gastrointestinal cancers.

Vaccines

Preventative vaccines including Gardasil (HPV), Vaxneuvance (pneumococcal), and MMR II.

Cardiometabolic & Infectious Diseases

Therapeutics for cardiovascular health, diabetes, HIV, and hospital-acquired infections.

Merck Animal Health

Veterinary pharmaceuticals, vaccines, and health management technology for livestock and pets.

Career Areas

Types of professional roles found inside Merck.

R&D Discovery & Clinical Research
Biotech & Pharmaceutical Engineering
Regulatory Affairs & Medical Safety
Global Manufacturing & Supply Chain
Biostatistics & Data Science
Commercial Strategy & Oncology Access
Finance & Enterprise Operations
People & Workplace Culture

Merck's History

1891
Merck USA Established
George Merck establishes Merck & Co. in Rahway, New Jersey.
1953
Merck & Sharp & Dohme Merge
Merges with Sharp & Dohme, creating a major pharmaceutical manufacturing giant.
2014
Keytruda FDA Approval
FDA approves Keytruda (pembrolizumab), revolutionizing immuno-oncology treatment.
2019
Peloton Therapeutics Acquisition
Acquires Peloton Therapeutics to expand kidney cancer drug development pipeline.
2023
Prometheus Biosciences Acquisition
Acquires Prometheus Biosciences for $10.8 billion to strengthen immunology assets.